drugset
drugset / Trial / NCT05363007

Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma

NCT05363007 ↗

Phase 2 Unknown 60 enrolled National Taiwan University Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Splenomegaly is common in advanced pancreatic ductal adenocarcinoma (PDAC). The spleen is an important source of immune suppressive cells and phagocytic cells and may mediate the accumulation of liposomal drugs and immunosuppression. In this study, spleen irradiation (SI) will be added to standard chemotherapy.

Timeline

Start
2022-05-01
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Background Irinotecan Small molecule 80 mg/m2 —
Background Leucovorin Small molecule 400 mg/m2 —
Background fluorouracil Small molecule 2400 mg/m2 —

Indications

malignant pancreatic neoplasm